Chloroquine
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1949
- First approval year
- 1949
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Chloroquine
- Molecular weight
- 319.88
- Structure (SMILES)
- CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12
- 1 4 pentanediamine n sup 4 7 chloro 4 quinolinyl n sup 1 n sup 1 diethyl
- 1,4-PENTANEDIAMINE, N(SUP 4)-(7-CHLORO-4-QUINOLINYL)-N(SUP 1),N (SUP 1)-DIETHYL-
- chloroquine
- Chloroquine
- CHLOROQUINE [HSDB]
- chloroquine [INN]
- CHLOROQUINE [MART.]
- CHLOROQUINE [MI]
- CHLOROQUINE [USP IMPURITY]
- CHLOROQUINE [USP MONOGRAPH]
- CHLOROQUINE [VANDF]
- Chloroquine [WHO-DD]
- chloroquine hsdb
- chloroquine inn
- chloroquine mart
- chloroquine mi
- chloroquine usp impurity
- chloroquine usp monograph
- chloroquine vandf
- chloroquine who dd
- cloroquina
- Cloroquina
- nsc 187208
- NSC-187208
- ATC classification codes
- P01BA01
Sources for recorded values
- CAS registry numbers
- 54-05-7
- ChEMBL ID
- CHEMBL76
- InChIKey
- WHTVZRBIWZFKQO-UHFFFAOYSA-N
- PubChem compound IDs
- 2719
- FDA ingredient codes (UNII)
- 886U3H6UFF
- 2393
- 203119
- Applicant
- SANOFI AVENTIS US
- Approval date
- 31 Oct 1949
- Application number
- NDA006002
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- United States (FDA)
- Approved
- Pharmacology name
- chloroquine
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- Action
- Agonist
- Action type
- Agonist
- Target
- MRGPRX1
- Gene symbol
- MRGPRX1
- Protein identifier
- Q96LB2
- Median affinity
- 3.53
- Affinity units
- pEC50
- Action
- Agonist
- Action type
- Agonist
- Target
- TAS2R3
- Gene symbol
- TAS2R3
- Protein identifier
- Q9NYW6
- Condition
- Carcinoma, Intraductal, Noninfiltrating
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000432
- Subject identifier
- D002285
- Condition
- Glioblastoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- HIV Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Acquired Immunodeficiency Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000765
- Subject identifier
- D000163
- Condition
- Malaria
- Highest recorded phase
- 4
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Multiple Myeloma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Pregnancy
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002950
- Subject identifier
- D011247
- Condition
- Severe Dengue
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004227
- Subject identifier
- D019595
- Condition
- Brain Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005774
- Subject identifier
- D001927
- Condition
- Influenza, Human
- Highest recorded phase
- 2
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
- Condition
- Malaria, Falciparum
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007444
- Subject identifier
- D016778
- Condition
- Malaria, Vivax
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007445
- Subject identifier
- D016780
- Condition
- Gliosarcoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001465
- Subject identifier
- D018316
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition
- Lupus Erythematosus, Systemic
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007915
- Subject identifier
- D008180
- Condition
- Anemia, Sickle Cell
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0011382
- Subject identifier
- D000755
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0000195
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000432
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000702
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000765
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000771
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001068
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002950
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004227
- Condition identifier
- EFO_0005774
- Highest recorded phase
- 2
- Condition identifier
- EFO_0007328
- Highest recorded phase
- 2
- Condition identifier
- EFO_0007444
- Condition identifier
- EFO_0007445
- Highest recorded phase
- 3
- Condition identifier
- HP_0001945
- Condition identifier
- HP_0006767
- Condition identifier
- MONDO_0003210
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004981
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005023
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005109
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005113
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005136
- Highest recorded phase
- 4
And 21 more, listed on the interactive page.
- Event
- abdominal discomfort
- Reports
- 1,234
- Reporting signal score
- 2,052.5
- Event
- acquired pigmented retinopathy
- Reports
- 2
- Reporting signal score
- 14.9849
- Event
- alopecia
- Reports
- 1,161
- Reporting signal score
- 1,842.54
- Event
- anti-cyclic citrullinated peptide antibody positive
- Reports
- 492
- Reporting signal score
- 1,834.77
- Event
- apparent death
- Reports
- 89
- Reporting signal score
- 235.327
- Event
- arthralgia
- Reports
- 1,902
- Reporting signal score
- 2,038.58
- Event
- arthritis
- Reports
- 412
- Reporting signal score
- 502.666
- Event
- arthropathy
- Reports
- 1,142
- Reporting signal score
- 2,590.17
- Event
- atrioventricular block complete
- Reports
- 10
- Reporting signal score
- 42.3374
- Event
- bipolar disorder
- Reports
- 3
- Reporting signal score
- 9.76516
- Event
- blister
- Reports
- 282
- Reporting signal score
- 302.796
- Event
- blood cholesterol increased
- Reports
- 214
- Reporting signal score
- 236.442
- Event
- blood iron abnormal
- Reports
- 158
- Reporting signal score
- 632.872
- Event
- blood parathyroid hormone decreased
- Reports
- 83
- Reporting signal score
- 237.591
- Event
- body height below normal
- Reports
- 67
- Reporting signal score
- 222.657
- Event
- bone density decreased
- Reports
- 101
- Reporting signal score
- 179.053
- Event
- bone erosion
- Reports
- 151
- Reporting signal score
- 443.52
- Event
- breast cancer stage iii
- Reports
- 63
- Reporting signal score
- 213.918
- Event
- c-reactive protein abnormal
- Reports
- 508
- Reporting signal score
- 1,796.39
- Event
- c-reactive protein increased
- Reports
- 571
- Reporting signal score
- 985.661
- Event
- cardiomyopathy
- Reports
- 6
- Reporting signal score
- 18.4789
- Event
- cardiotoxicity
- Reports
- 5
- Reporting signal score
- 17.5714
- Event
- colour vision tests abnormal red-green
- Reports
- 1
- Reporting signal score
- 8.5851
- Event
- condition aggravated
- Reports
- 1,605
- Reporting signal score
- 1,777.53
- Event
- corneal deposits
- Reports
- 3
- Reporting signal score
- 15.844
And 97 more, listed on the interactive page.
- NCT00074841
- NCT00082563
- NCT00082576
- NCT00084227
- NCT00084240
- NCT00158548
- NCT00282919
- NCT00379821
- NCT00677833
- NCT00682578
- NCT00959517
- NCT02773979
- NCT02996695
- NCT00118807
- NCT00131703
- NCT00290420
- NCT00323375
- NCT00367653
- NCT00440999
- NCT00442403
- NCT00844207
- NCT00871156
- NCT01100060
- NCT01205178
- NCT01290601
And 59 more, listed on the interactive page.
- Dose
- 300mg
- How often
- Once per week
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 28.16
- Calculated partition coefficient (ALogP)
- 4.81
- Calculated partition coefficient (XLogP)
- 4.6
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 8
- Heavy atoms
- 22
- Molecular formula
- C18H26ClN3
- Monoisotopic mass
- 319.1815255
- Natural product
- Yes
- Recorded assays
- 7,594
- Active assays
- 2,256
- Confirmatory
- Other
- Screening
- Amebicides
- Antimalarials
- Antirheumatic Agents
These details could not be displayed.
Related records
Trials (132)
- "Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"
- A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
- A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria
- A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects
- A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine
- A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer
- A Randomized Controlled Trial for Intermittent Preventive Treatment in Pregnancy With Fansidar in Solomon Islands
- A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis
- A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh
- A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria
- Acceptability and Cost Effectiveness of Home Based Management of Fever: Different Strategies
- ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
- Adjuvant Effect of Chloroquine on Gemcitabine
- An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older
- Antimalarial Drug Resistance in Mali
- Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam
- Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia
- Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria
- Assessing a Risk Model for G6PD Deficiency
- Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
Approved for (1)
In development for (29)
- AIDS Phase 2
- Atrial fibrillation Phase 2
- Bacterial infectious disease Phase 3
- Brain disorder Phase 2
- Breast cancer Phase 2
- Cancer Phase 1
- Chondrosarcoma Phase 1
- COVID-19 Phase 3
- Dengue hemorrhagic fever Phase 1
- Ductal breast carcinoma in situ Phase 1
- Exocrine pancreatic carcinoma Phase 1
- Glioblastoma Phase 3
- Glioma Phase 1
- Gliosarcoma Phase 1
- HIV infectious disease Phase 2
- Influenza Phase 2
- Intrahepatic cholangiocarcinoma Phase 1
- Malignant pancreatic neoplasm Phase 1
- Melanoma Phase 1
- Pancreatic neoplasm Phase 1
Other linked conditions (3)
- Atherosclerosis
- Lupus nephritis
- Prolactin-producing pituitary gland adenoma